<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To compare the clinical outcomes between HLA allele matched (HLA-M) and 1 approximately 2 alleles disparity mismatched (HLA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e>) unrelated allogeneic bone marrow transplantation (URD-BMT) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Thirty-nine patients received HLA-M and 21 received HLA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e> URD-BMT for the treatment of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase (CP) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in our hospital between November 1998 and December 2002 </plain></SENT>
<SENT sid="2" pm="."><plain>Conditioning regimen was Bu 16 mg/kg plus <z:chebi fb="3" ids="3498">CTX</z:chebi> 120 mg/kg, and <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil (MMF), CsA and MTX were given to prevent aGVHD </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Thirty-eight of the HLA-M group and 18 of the HLA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e> group were engrafted successfully </plain></SENT>
<SENT sid="4" pm="."><plain>The median follow-up duration was 11 (2.5 - 52.0) months for HLA-M group and 9 (2 - 46) months for HLA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e> group </plain></SENT>
<SENT sid="5" pm="."><plain>The 3-year probabilities of disease-free survival (DFS) for HLA-M and HLA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e> group were (79.2 +/- 7.1)% and (45.8 +/- 15.5)%, respectively (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Grade II - IV aGVHD occurred in 10 (26.3%) patients in HLA-M group and 6 (33.3%) in HLA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e> group, respectively (P &gt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: URD-BMT is an effective modality for the treatment of <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The outcome after URD-BMT can be optimized by matching the HLA-A, B and DR alleles between the donor and recipient </plain></SENT>
</text></document>